New Indication: Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma

Phase II, open-label, single-arm study

Cisplatin-fit resectable cT2-T4a,cN0-N1 MIUC

GC+ Durvalumab followed by surgery followed by Durvalumab maintenance

2-year EFS: 76% [62-85]

3-year EFS: 73% [59-83]

3-year OS: 81% [67-89]

cPR: 33% [17 of 52 pts]

Grade≥ 3: Neutrophenia (21%), thrombocytopenia (21%), anemia (18%)

Cathomas Richard et al. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17

Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023